Literature DB >> 11410643

Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans.

M A Tarnopolsky1, G Parise, M J Gibala, T E Graham, J W Rush.   

Abstract

1. Myoadenylate deaminase (AMPD) deficiency is present in 1--2 % of the population. In theory, this deficiency may alter exercise energy metabolism by impairing the purine nucleotide cycle (PNC) and reducing tricarboxylic acid (TCA) cycle anaplerosis. The role of the PNC in TCA cycle anaplerosis is still a debated issue in physiology. Using patients with the AMPD1 mutation will allow a human 'knockout' approach to answering this question. 2. Muscle AMPD activity and genotype (whole blood AMPD1 analysis) was used to classify participants into three groups: n = 3 with absence of AMPD activity and -/- AMPD1 genotype (homozygous); n = 4 with less than 50 % normal AMPD activity and +/- genotype (heterozygous) and n = 12 with normal AMPD activity and +/+ genotype (control). Biopsies were taken from the vastus lateralis muscle before and after incremental cycle ergometry exercise to exhaustion. The muscle biopsies were analysed for AMPD activity, purine nucleotides/nucleosides and bases, creatine, phosphocreatine, amino acids, and the TCA cycle intermediates malate, citrate and fumarate. 3. Time to exhaustion on the cycle ergometer was not different between groups. Muscle adenosine monophosphate increased significantly with exercise for homozygous subjects as compared with the other groups (P < 0.05). Inosine monophosphate increased significantly after exercise for control (P < 0.05) but not for the homozygous subjects. There were no other between-group differences for any other measured variables. 4. In summary, complete and partial muscle AMPD deficiency did not affect TCA cycle anaplerosis, phosphocreatine hydrolysis, energy charge or exercise performance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11410643      PMCID: PMC2278656          DOI: 10.1111/j.1469-7793.2001.t01-1-00881.x

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  30 in total

1.  Primary, secondary, and coincidental types of myoadenylate deaminase deficiency.

Authors:  W N Fishbein
Journal:  Ann Neurol       Date:  1999-04       Impact factor: 10.422

2.  Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease.

Authors:  M A Tarnopolsky; G Parise
Journal:  Muscle Nerve       Date:  1999-09       Impact factor: 3.217

3.  Clinical, physiological, and histological features in a kindred with the T3271C melas mutation.

Authors:  M A Tarnopolsky; J Maguire; T Myint; D Applegarth; B H Robinson
Journal:  Muscle Nerve       Date:  1998-01       Impact factor: 3.217

4.  Molecular and kinetic alterations of muscle AMP deaminase during chronic creatine depletion.

Authors:  J W Rush; P C Tullson; R L Terjung
Journal:  Am J Physiol       Date:  1998-02

Review 5.  Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency.

Authors:  M Gross
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

6.  Control of AMP deaminase 1 binding to myosin heavy chain.

Authors:  I Hisatome; T Morisaki; H Kamma; T Sugama; H Morisaki; A Ohtahara; E W Holmes
Journal:  Am J Physiol       Date:  1998-09

7.  Tricarboxylic acid cycle intermediates in human muscle at rest and during prolonged cycling.

Authors:  M J Gibala; M A Tarnopolsky; T E Graham
Journal:  Am J Physiol       Date:  1997-02

8.  Genetic and other determinants of AMP deaminase activity in healthy adult skeletal muscle.

Authors:  B Norman; D K Mahnke-Zizelman; A Vallis; R L Sabina
Journal:  J Appl Physiol (1985)       Date:  1998-10

9.  Genetic characteristics of myoadenylate deaminase deficiency.

Authors:  H T Verzijl; B G van Engelen; J A Luyten; G C Steenbergen; L P van den Heuvel; H J ter Laak; G W Padberg; R A Wevers
Journal:  Ann Neurol       Date:  1998-07       Impact factor: 10.422

10.  Tricarboxylic acid cycle intermediates during incremental exercise in healthy subjects and in patients with McArdle's disease.

Authors:  K Sahlin; L Jorfeldt; K G Henriksson; S F Lewis; R G Haller
Journal:  Clin Sci (Lond)       Date:  1995-06       Impact factor: 6.124

View more
  14 in total

1.  C34T mutation of the AMPD1 gene in an elite white runner.

Authors:  A Lucia; M A Martin; J Esteve-Lanao; A F San Juan; J C Rubio; J Oliván; J Arenas
Journal:  Br J Sports Med       Date:  2006-03       Impact factor: 13.800

2.  The effect of AMPD1 genotype on blood flow response to sprint exercise.

Authors:  Barbara Norman; Anders T Nygren; Jacek Nowak; Richard L Sabina
Journal:  Eur J Appl Physiol       Date:  2008-01-26       Impact factor: 3.078

3.  C34T mutation of the AMPD1 gene in an elite white runner.

Authors:  Alejandro Lucia; Miguel A Martin; Jonathan Esteve-Lanao; Alejandro F San Juan; Juan C Rubio; Jesús Oliván; Joaquín Arenas
Journal:  BMJ Case Rep       Date:  2009-01-23

4.  Immunohistochemical analysis of human skeletal muscle AMP deaminase deficiency. Evidence of a correlation between the muscle HPRG content and the level of the residual AMP deaminase activity.

Authors:  Antonietta R M Sabbatini; Antonio Toscano; Mohammed Aguennouz; Daniela Martini; Enza Polizzi; Maria Ranieri-Raggi; Arthur J G Moir; Alba Migliorato; Olimpia Musumeci; Giuseppe Vita; Antonio Raggi
Journal:  J Muscle Res Cell Motil       Date:  2006-03-29       Impact factor: 2.698

Review 5.  Uric acid changes in urine and plasma: an effective tool in screening for purine inborn errors of metabolism and other pathological conditions.

Authors:  R E Simoni; L N L Ferreira Gomes; F B Scalco; C P H Oliveira; F R Aquino Neto; M L Costa de Oliveira
Journal:  J Inherit Metab Dis       Date:  2007-05-19       Impact factor: 4.982

6.  Diagnostic Algorithm for Glycogenoses and Myoadenylate Deaminase Deficiency Based on Exercise Testing Parameters: A Prospective Study.

Authors:  Fabrice Rannou; Arnaud Uguen; Virginie Scotet; Cédric Le Maréchal; Odile Rigal; Pascale Marcorelles; Eric Gobin; Jean-Luc Carré; Fabien Zagnoli; Marie-Agnès Giroux-Metges
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

7.  Effects of AMPD1 common mutation on the metabolic-chronotropic relationship: Insights from patients with myoadenylate deaminase deficiency.

Authors:  Fabrice Rannou; Virginie Scotet; Pascale Marcorelles; Roxane Monnoyer; Cédric Le Maréchal
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

8.  Control of ATP homeostasis during the respiro-fermentative transition in yeast.

Authors:  Thomas Walther; Maite Novo; Katrin Rössger; Fabien Létisse; Marie-Odile Loret; Jean-Charles Portais; Jean-Marie François
Journal:  Mol Syst Biol       Date:  2010-01-19       Impact factor: 11.429

9.  AMPD1 rs17602729 is associated with physical performance of sprint and power in elite Lithuanian athletes.

Authors:  Valentina Ginevičienė; Audronė Jakaitienė; Aidas Pranculis; Kazys Milašius; Linas Tubelis; Algirdas Utkus
Journal:  BMC Genet       Date:  2014-05-17       Impact factor: 2.797

Review 10.  Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis.

Authors:  Ai-Fang Feng; Zhong-Hui Liu; Shu-Long Zhou; Shi-Yuan Zhao; Yan-Xin Zhu; Huai-Xin Wang
Journal:  BMC Cardiovasc Disord       Date:  2017-07-03       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.